KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies.
about
Molecular biology of lung cancerMolecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancersK-Ras Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive ValueMolecular pathology of lung cancer: key to personalized medicine.Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.KRAS mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patientsInternational association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinomaLung Cancer Gene Signatures and Clinical PerspectivesTime-to-Progression of NSCLC from Early to Advanced Stages: An Analysis of data from SEER Registry and a Single Institute.Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study.Reduced NF1 expression confers resistance to EGFR inhibition in lung cancerEast meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians.Molecular pathways and therapeutic targets in lung cancerKRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer.Review of the use of pretest probability for molecular testing in non-small cell lung cancer and overview of new mutations that may affect clinical practice.BRAF mutations in patients with non-small cell lung cancer: a systematic review and meta-analysis.Racial disparity in metabolic regulation of cancer.Screening for EGFR and KRAS mutations in endobronchial ultrasound derived transbronchial needle aspirates in non-small cell lung cancer using COLD-PCR.Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status.EGFR and K-Ras mutations in women with lung adenocarcinoma: implications for treatment strategy definition.Novel agents in development for advanced non-small cell lung cancer.KRAS driven expression signature has prognostic power superior to mutation status in non-small cell lung cancer.Coexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancer.Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer.Tailoring tyrosine kinase inhibitors to fit the lung cancer genome.Efficacy and safety profile of combining vandetanib with chemotherapy in patients with advanced non-small cell lung cancer: a meta-analysis.Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC.From the bench to bedside: biological and methodology considerations for the future of companion diagnostics in nonsmall cell lung cancer.Molecularly targeted therapies in non-small-cell lung cancer annual update 2014Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalitiesFollowing the crumbs: from tissue samples, to pharmacogenomics, to NSCLC therapyKRAS status and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis.Defining the role of tyrosine kinase inhibitors in early stage non-small cell lung cancer.Personalizing therapy with targeted agents in non-small cell lung cancerPrognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomasPredictive value of K-ras and PIK3CA in non-small cell lung cancer patients treated with EGFR-TKIs: a systemic review and meta-analysis.L858R-positive lung adenocarcinoma with KRAS G12V, EGFR T790M and EGFR L858R mutations: A case report.Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients.The role of molecular pathology in non-small-cell lung carcinoma-now and in the future.PNA clamping-assisted fluorescence melting curve analysis for detecting EGFR and KRAS mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancer
P2860
Q24606677-38CDBB14-9757-451D-A186-74217ACC2197Q24611043-D050474F-C38E-4EF6-B108-E7545EB2586BQ26829425-8678550C-26DB-43C5-9CD1-36437B945B6BQ27691299-00DAC53F-9BCE-4818-9422-7008F7B8CC0DQ27851628-8BD6A6A9-A237-4EAF-A889-EA0582E0AE80Q28077570-6E496AA4-ABE5-4F41-8B0C-326C0C33CBB6Q28303718-A29E85BB-36CF-4927-B869-2C7AEEBA7796Q28387769-5C1A9BA5-F897-489A-9845-32F88CE69758Q31110762-D93F5DAC-E092-4C10-A60B-8D3600DF46D6Q33407582-C9765F6F-3AC0-42C0-8A07-CAE214127A70Q33572728-656CA22F-A9DD-4558-974B-92D25E490818Q33579631-3F285AA5-B525-4D24-9E44-F1497CA367ACQ33688872-152A6437-6437-43B7-99E0-E99CB71A6891Q33690682-6986166A-AAEB-498C-9DE0-BD92BA3B1A34Q33757138-B881FF1B-F131-4000-8F6D-E202CB5E73BCQ33826001-EF9539CB-9171-4DD8-86D3-6CFD36F3A10DQ33906704-75002E93-0360-4A0D-B24B-1203AD7A45EFQ34032012-6C4D830A-3AAF-42CD-86C4-B48F8247A551Q34328665-6331C16A-1672-453F-ADE3-F122CB898621Q34346624-3AA1B582-C8EB-4E91-8E91-73F657BFEE44Q34389263-C75A8B94-A666-4C1E-995C-00311C53757CQ34544971-E0A828E1-A0F4-4156-A432-3C1DD898C5DCQ34658204-4B90BF9E-3C0A-43ED-B3AB-17F7CD301778Q34749852-ECD5D862-1EBE-4C46-8810-D66B9E843987Q34754045-00920E8B-A6FB-4EAA-A59D-E4953202BFE1Q34826532-59AB27AA-4C56-44AB-8528-177403CCEBD6Q35034044-07060C40-5C0B-44BF-B359-ED729EAD8B74Q35117568-1FBBE79A-640D-4887-881F-AEE9A8A4AC64Q35136424-E05EF885-7BE7-43A3-81A5-6D39F47157BAQ35146927-416DB696-9B98-420F-A8AD-870621DD4DD4Q35200424-8C3B0609-2CA6-458F-BDEC-1D05B44EF641Q35231369-C326A26B-1379-4A87-99D6-A6977ECBA6EFQ35631635-2CEC8F8C-E0F2-4F98-9A96-BD8D9F23646BQ35679361-49006A98-4675-4496-A268-A436449E7015Q35775729-986464C5-4678-4B43-A42B-572C7AD5DB3AQ35824117-F5AAE2F0-A2BE-4C7E-9A55-8984200AF5F6Q35943143-19A48BDD-DD63-4555-B48B-15692A87072AQ35956330-A72C237F-7E58-452F-9AE5-37CE3A5EAD3CQ36040599-833A8736-F2F6-472E-8977-A9555FE54058Q36103228-2056ECCC-59FC-4561-BBFB-B2FCE7A361D7
P2860
KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
KRAS mutations and resistance ...... a meta-analysis of 22 studies.
@en
KRAS mutations and resistance ...... a meta-analysis of 22 studies.
@nl
type
label
KRAS mutations and resistance ...... a meta-analysis of 22 studies.
@en
KRAS mutations and resistance ...... a meta-analysis of 22 studies.
@nl
prefLabel
KRAS mutations and resistance ...... a meta-analysis of 22 studies.
@en
KRAS mutations and resistance ...... a meta-analysis of 22 studies.
@nl
P2093
P1433
P1476
KRAS mutations and resistance ...... a meta-analysis of 22 studies.
@en
P2093
Fang-Bing Du
Li-Xin Qiu
Ru-Yan Liao
Wan-Chun Yang
P304
P356
10.1016/J.LUNGCAN.2009.11.020
P577
2009-12-22T00:00:00Z